Dual clinical remission in patients treated with biologics for severe asthma and eosinophilic chronic rhinosinusitis - PubMed
5 hours ago
- #Biologics
- #Clinical Remission
- #Eosinophilic Chronic Rhinosinusitis
- Study evaluates dual clinical remission (CR) in patients with severe asthma (SA) and eosinophilic chronic rhinosinusitis (ECRS) treated with biologics.
- 67 patients with both SA and ECRS were retrospectively analyzed after receiving biologics for ≥12 months.
- CR for SA was achieved in 37% of patients, while CR for ECRS was achieved in 60%.
- Dual CR (for both conditions) occurred in 25% of patients.
- Predictors of dual CR included age ≥65 years and presence of nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD).
- Biologics used included omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab, and combinations.